Cutaneous squamous cell carcinoma: an epidemiological review

British Journal of Dermatology

Volumn 177, Issue 2, 2017, Pages 373-381

  Green, A C ^a,b   Olsen, C M ^a,c  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; EFLORNITHINE; FLUOROURACIL; NICOTINAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SUNSCREEN;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CHEMOPROPHYLAXIS; GENETIC PREDISPOSITION; HUMAN; META ANALYSIS (TOPIC); PRECANCER; PRIMARY PREVENTION; PRIORITY JOURNAL; RADIATION PROTECTION; REVIEW; RISK FACTOR; SKIN CANCER; SKIN CARCINOMA; SKIN PROTECTION; SYSTEMATIC REVIEW (TOPIC); ULTRAVIOLET RADIATION; DEMOGRAPHY; ENVIRONMENTAL EXPOSURE; GLOBAL HEALTH; INCIDENCE; PROCEDURES; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; STATISTICS AND NUMERICAL DATA;

CARCINOMA, SQUAMOUS CELL; CHEMOPREVENTION; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION TO DISEASE; GLOBAL HEALTH; HUMANS; INCIDENCE; PRIMARY PREVENTION; RESIDENCE CHARACTERISTICS; RISK FACTORS; SKIN NEOPLASMS;

EID: 85013447177     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.15324     Document Type: Review

References (98)

1. Gordon LG, Rowell D. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: systematic review. Eur J Cancer Prev 2015; 24:141–9.
2. Vallejo-Torres L, Morris S, Kinge JM et al. Measuring current and future cost of skin cancer in England. J Public Health (Oxf) 2014; 36:140–8.
3. Gordon LG, Elliott TM, Wright CY et al. Modelling the healthcare costs of skin cancer in South Africa. BMC Health Serv Res 2016; 16:113.
4. Guy GP Jr, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the U.S., 2002–2006 and 2007–2011. Am J Prev Med 2015; 48:183–7.
5. Wallingford SC, Olsen CM, Plasmeijer E et al. Skin cancer arising in scars: a systematic review. Dermatol Surg 2011; 37:1239–44.
6. Yakubu A, Mabogunje OA. Squamous cell carcinoma of the skin in Africans. Trop Geogr Med 1995; 47:91–3.
7. Green AC. Epidemiology of actinic keratoses. Curr Prob Dermatol 2015; 46:1–7.
8. Quaedvlieg PJ, Tirsi E, Thissen MR et al. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 2006; 16:335–9.
9. Werner RN, Sammain A, Erdmann R et al. The natural history of actinic keratosis: a systematic review. Br J Dermatol 2013; 169:502–18.
10. Wallingford SC, Russell SA, Vail A et al. Actinic keratoses, actinic field change and associations with squamous cell carcinoma in renal transplant recipients in Manchester. UK. Acta Derm Venereol 2015; 95:830–4.
11. Jiyad Z, O'Rourke P, Soyer HP, Green AC. Actinic keratosis-related signs predictive of squamous cell carcinoma in renal transplant recipients: a nested case–control study. Br J Dermatol 2016; DOI: 10.1111/bjd.15019
12. Kyrgidis A, Tzellos TG, Kechagias N et al. Cutaneous squamous cell carcinoma (SCC) of the head and neck: risk factors of overall and recurrence-free survival. Eur J Cancer 2010; 46:1563–72.
13. Schmults CD, Karia PS, Carter JB et al. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol 2013; 149:541–7.
14. Levine DE, Karia PS, Schmults CD. Outcomes of patients with multiple cutaneous squamous cell carcinomas: a 10-year single-institution cohort study. JAMA Dermatol 2015; 151:1220–5.
15. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166:1069–80.
16. Jung GW, Metelitsa AI, Dover DC et al. Trends in incidence of nonmelanoma skin cancers in Alberta, Canada, 1988–2007. Br J Dermatol 2010; 163:146–54.
17. Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985–1996. J Am Acad Dermatol 2001; 45:528–36.
18. Robsahm TE, Helsing P, Veierod MB. Cutaneous squamous cell carcinoma in Norway 1963–2011: increasing incidence and stable mortality. Cancer Med 2015; 4:472–80.
19. Staples MP, Elwood M, Burton RC et al. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust 2006; 184:6–10.
20. Deady S, Sharp L, Comber H. Increasing skin cancer incidence in young, affluent, urban populations: a challenge for prevention. Br J Dermatol 2014; 171:324–31.
21. de Vries E, van de Poll-Franse LV, Louwman WJ et al. Predictions of skin cancer incidence in the Netherlands up to 2015. Br J Dermatol 2005; 152:481–8.
22. Dal H, Boldemann C, Lindelof B. Trends during a half century in relative squamous cell carcinoma distribution by body site in the Swedish population: support for accumulated sun exposure as the main risk factor. J Dermatol 2008; 35:55–62.
23. Boyers LN, Karimkhani C, Naghavi M et al. Global mortality from conditions with skin manifestations. J Am Acad Dermatol 2014; 71:1137–43.e17.
24. Wu W, Weinstock MA. Trends of keratinocyte carcinoma mortality rates in the United States as reported on death certificates, 1999 through 2010. Dermatol Surg 2014; 40:1395–401.
25. Eisemann N, Jansen L, Castro FA et al. Survival with nonmelanoma skin cancer in Germany. Br J Dermatol 2016; 174:778–85.
26. Garrett GL, Lowenstein SE, Singer JP et al. Trends of skin cancer mortality after transplantation in the United States: 1987 to 2013. J Am Acad Dermatol 2016; 75:106–12.
27. International Agency for Research on Cancer. Solar and UV radiation. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Radiation 2012; 100D:35–101.
28. Ramos J, Villa J, Ruiz A et al. UV dose determines key characteristics of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev 2004; 13:2006–11.
29. Rosso S, Zanetti R, Martinez C et al. The multicentre south European study ‘Helios’. II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996; 73:1447–54.
30. Brash DE. UV signature mutations. Photochem Photobiol 2015; 91:15–26.
31. Park WS, Lee HK, Lee JY et al. p53 mutations in solar keratoses. Hum Pathol 1996; 27:1180–4.
32. Wehner MR, Shive ML, Chren MM et al. Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ 2012; 345:e5909.
33. English DR, Armstrong BK, Kricker A et al. Case–control study of sun exposure and squamous cell carcinoma of the skin. Int J Cancer 1998; 77:347–53.
34. Aubry F, MacGibbon B. Risk factors of squamous cell carcinoma of the skin. A case–control study in the Montreal region. Cancer 1985; 55:907–11.
35. Grodstein F, Speizer FE, Hunter DJ. A prospective study of incident squamous cell carcinoma of the skin in the Nurses' Health Study. J Natl Cancer Inst 1995; 87:1061–6.
36. Lindelof B, Sigurgeirsson B, Tegner E et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999; 141:108–12.
37. Mudigonda T, Levender MM, O'Neill JL et al. Incidence, risk factors, and preventative management of skin cancers in organ transplant recipients. Derm Surg 2013; 39:345–64.
38. Zhao H, Shu G, Wang S. The risk of non-melanoma skin cancer in HIV-infected patients: new data and meta-analysis. Int J STD AIDS 2016; 27:568–75.
39. Brewer JD, Shanafelt TD, Khezri F et al. Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a Rochester Epidemiology Project population-based study in Minnesota. J Am Acad Dermatol 2015; 72:302–9.
40. Levi F, Randimbison L, Te VC et al. Non-Hodgkin's lymphomas, chronic lymphocytic leukaemias and skin cancers. Br J Cancer 1996; 74:1847–50.
41. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348:1681–91.
42. Amari W, Zeringue AL, McDonald JR et al. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatol 2011; 50:1431–9.
43. Long MD, Martin CF, Pipkin CA et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterol 2012; 143:390–9.e1.
44. Karagas MR, Cushing GL Jr, Greenberg ER et al. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001; 85:683–6.
45. Jensen AO, Thomsen HF, Engebjerg MC et al. Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case–control study. Br J Cancer 2009; 100:200–5.
46. Sorensen HT, Mellemkjaer L, Nielsen GL et al. Skin cancers and non-Hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004; 96:709–11.
47. Gallagher RP, Bajdik CD, Fincham S et al. Chemical exposures, medical history, and risk of squamous and basal cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev 1996; 5:419–24.
48. Gawkrodger DJ. Occupational skin cancers. Occup Med (Lond) 2004; 54:458–63.
49. Kennedy C, Bajdik CD, Willemze R et al. Chemical exposures other than arsenic are probably not important risk factors for squamous cell carcinoma, basal cell carcinoma and malignant melanoma of the skin. Br J Dermatol 2005; 152:194–7.
50. Lichter MD, Karagas MR, Mott LA et al. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol 2000; 136:1007–11.
51. Song F, Qureshi AA, Gao X et al. Smoking and risk of skin cancer: a prospective analysis and a meta-analysis. Int J Epidemiol 2012; 41:1694–705.
52. Leonardi-Bee J, Ellison T, Bath-Hextall F. Smoking and the risk of nonmelanoma skin cancer: systematic review and meta-analysis. Arch Dermatol 2012; 148:939–46.
53. de Villiers EM. Cross-roads in the classification of papillomaviruses. Virology 2013; 445:2–10.
54. Hall L, Struijk L, Neale RE et al. Re: Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 2006; 98:1425–6.
55. Karagas MR, Nelson HH, Sehr P et al. Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 2006; 98:389–95.
56. Andersson K, Waterboer T, Kirnbauer R et al. Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions. Cancer Epidemiol Biomarkers Prev 2008; 17:189–95.
57. Plasmeijer EI, Pandeya N, O'Rourke P et al. The association between cutaneous squamous cell carcinoma and betapapillomavirus seropositivity: a cohort study. Cancer Epidemiol Biomarkers Prev 2011; 20:1171–7.
58. Pfister H. Chapter 8: Human papillomavirus and skin cancer. J Natl Cancer Inst Monogr 2003; 31:52–6.
59. Pacini L, Savini C, Ghittoni R et al. Downregulation of Toll-like receptor 9 expression by beta human papillomavirus 38 and implications for cell cycle control. J Virol 2015; 89:11396–405.
60. McLaughlin-Drubin ME. Human papillomaviruses and non-melanoma skin cancer. Sem Oncol 2015; 42:284–90.
61. Pothiawala S, Qureshi AA, Li Y et al. Obesity and the incidence of skin cancer in US Caucasians. Cancer Causes Control 2012; 23:717–26.
62. Lahmann PH, Hughes MCB, Williams GM et al. A prospective study of measured body size and height and risk of keratinocyte cancers and melanoma. Cancer Epidemiol 2016; 40:119–25.
63. Hughes MC, Williams GM, Fourtanier A et al. Food intake, dietary patterns, and actinic keratoses of the skin: a longitudinal study. Am J Clin Nutr 2009; 89:1246–55.
64. Siiskonen S, Han J, Li T et al. Alcohol intake is associated with increased risk of squamous cell carcinoma of the skin: three US prospective cohort studies. Nutr Cancer 2016; 68:545–53.
65. Ansems TM, van der Pols JC, Hughes MC et al. Alcohol intake and risk of skin cancer: a prospective study. Eur J Clin Nutr 2008; 62:162–70.
66. Lahmann PH, Russell A, Green AC. Prospective study of physical activity and risk of squamous cell carcinoma of the skin. BMC Cancer 2011; 11:516.
67. Birch-Johansen F, Jensen A, Olesen AB et al. Does hormone replacement therapy and use of oral contraceptives increase the risk of non-melanoma skin cancer? Cancer Causes Control 2012; 23:379–88.
68. Applebaum KM, Nelson HH, Zens MS et al. Oral contraceptives: a risk factor for squamous cell carcinoma? J Invest Dermatol 2009; 129:2760–5.
69. Asgari MM, Efird JT, Warton EM et al. Potential risk factors for cutaneous squamous cell carcinoma include oral contraceptives: results of a nested case–control study. Int J Environ Res Public Health 2010; 7:427–42.
70. Nikolaou V, Stratigos AJ, Tsao H. Hereditary nonmelanoma skin cancer. Sem Cutan Med Surg 2012; 31:204–10.
71. Jaju PD, Ransohoff KJ, Tang JY et al. Familial skin cancer syndromes: increased risk of nonmelanotic skin cancers and extracutaneous tumors. J Am Acad Dermatol 2016; 74:437–51; quiz 52–4.
72. Box NF, Duffy DL, Irving RE et al. Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma. J Invest Dermatol 2001; 116:224–9.
73. Tagliabue E, Fargnoli MC, Gandini S et al. MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project. Br J Cancer 2015; 113:354–63.
74. Nan H, Kraft P, Hunter DJ et al. Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int J Cancer 2009; 125:909–17.
75. Han J, Qureshi AA, Nan H et al. A germline variant in the interferon regulatory factor 4 gene as a novel skin cancer risk locus. Cancer Res 2011; 71:1533–9.
76. Nan H, Xu M, Kraft P et al. Genome-wide association study identifies novel alleles associated with risk of cutaneous basal cell carcinoma and squamous cell carcinoma. Hum Mol Genet 2011; 20:3718–24.
77. Siiskonen SJ, Zhang M, Li WQ et al. A genome-wide association study of cutaneous squamous cell carcinoma among European descendants. Cancer Epidemiol Biomarkers Prev 2016; 25:714–20.
78. Asgari MM, Wang W, Ioannidis NM et al. Identification of susceptibility loci for cutaneous squamous cell carcinoma. J Invest Dermatol 2016; 136:930–7.
79. Chahal HS, Lin Y, Ransohoff KJ et al. Genome-wide association study identifies novel susceptibility loci for cutaneous squamous cell carcinoma. Nat Commun 2016; 7:12048.
80. Mounessa J, Qin R, Dunnick CA, Dellavalle RP. Chemoprevention of keratinocyte carcinomas: an updated review. Am J Clin Dermatol 2016; 17:475–84.
81. Chen AC, Martin AJ, Damian DL. Nicotinamide for skin-cancer chemoprevention. N Engl J Med 2016; 374:790.
82. Kreul SM, Havighurst T, Kim K et al. A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity. Cancer Prev Res (Phila) 2012; 5:1368–74.
83. Muranushi C, Olsen CM, Pandeya N et al. Aspirin and nonsteroidal anti-inflammatory drugs can prevent cutaneous squamous cell carcinoma: a systematic review and meta-analysis. J Invest Dermatol 2015; 135:975–83.
84. Janda M, Green AC. Primary prevention of skin cancer. In: Evidence-Based Dermatology (Williams HC, Bigby M, Herxheimer A, Naldi L, Rzany B, Dellavalle RP et al., eds), Vol. 3. Oxford: John Wiley & Sons Ltd, 2014; 223–30.
85. Green AC, Williams GM. Point: sunscreen use is a safe and effective approach to skin cancer prevention. Cancer Epidemiol Biomarkers Prev 2007; 16:1921–2.
86. Green A, Williams G, Neale R et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354:723–9.
87. van der Pols JC, Williams GM, Pandeya N et al. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomarkers Prev 2006; 15:2546–8.
88. Darlington S, Williams G, Neale R et al. A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Arch Dermatol 2003; 139:451–5.
89. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993; 329:1147–51.
90. NICE. NICE Public Health Guidance 6: Behaviour change at population, community and individual levels. London: National Institute for Health and Clinical Excellence, 2007.
91. Jackson KM, Aiken LS. Evaluation of a multicomponent appearance-based sun-protective intervention for young women: uncovering the mechanisms of program efficacy. Health Psychol 2006; 25:34–46.
92. Lin JS, Eder M, Weinmann S. Behavioral counseling to prevent skin cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 154:190–201.
93. Moyer VA. Behavioral counseling to prevent skin cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:59–65.
94. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47:1–17; quiz 8–20.
95. Pawlak MT, Bui M, Amir M et al. Legislation restricting access to indoor tanning throughout the world. Arch Dermatol 2012; 148:1006–12.
96. Pan M, Geller L. Update on indoor tanning legislation in the United States. Clin Dermatol 2015; 33:387–92.
97. Sinclair CA, Makin JK, Tang A et al. The role of public health advocacy in achieving an outright ban on commercial tanning beds in Australia. Am J Public Health 2014; 104:e7–9.
98. Muranushi C, Olsen CM, Green AC et al. Can oral nonsteroidal antiinflammatory drugs play a role in the prevention of basal cell carcinoma? A systematic review and metaanalysis. J Am Acad Dermatol 2016; 74:108–19.e1.